Magnesium Pms Randomized Trial: What the Evidence Says

Quick Answer

Magnesium Pms Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Moreover, taking such drugs during Ramadan has been reported to increase the risk of cerebral venous thrombosis, and psychological resistance remains a major global challenge. [Iimura Jun (2026); evidence level 2]
• For instance, Ahmadi reported that zinc supplementation reduced PMD symptoms, and Tartagni reported the same for vitamin D. [Iimura Jun (2026); evidence level 2]
• PMD significantly impacts the overall health and well-being of women, contributing to higher levels of depression, anxiety, suicidal risk, impaired social and educational/work performance, and lower quality of life. [Krupa Anna Julia (2025); evidence level 4]
• It is estimated that 10% of women with PMDD have bipolar disorder, which poses a 7-fold higher risk compared to women without PMDD. [Krupa Anna Julia (2025); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For magnesium pms randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Iimura Jun (2026). Novel dietary FemTech based on dietary reference intakes for premenstrual and menstrual disorders: a pilot open-label randomized controlled trial of dietary intervention. DOI: 10.1186/s12905-026-04382-6. PMCID: PMC13019880. PMID: 41803877. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13019880/
• Krupa Anna Julia (2025). Zinc, copper, and magnesium in premenstrual disorders: a narrative review. DOI: 10.1007/s43440-025-00791-w. PMCID: PMC12647176. PMID: 41091414. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12647176/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.